CPO Quality
About the job
- A bachelor's degree or higher from an accredited university, completed and verified before starting, or a high school diploma/GED from an accredited institution plus at least 11 years of experience in a healthcare-related field or in business.
- Eight years of experience in Documentation Integrity for clinical, quality, and coding.
- Five years working in or with hospitals across revenue cycle areas, including physician documentation, CDI, Quality, and coding.
- Three years working with Solventum Physician, CDI, Quality, or Coding solutions and services.
- Define and communicate the long-term vision, strategy, and roadmap for outpatient and inpatient Quality products and capabilities.
- Align product strategies with organizational goals, regulatory requirements, customer needs, and market trends.
- Own the Quality product portfolio for Solventum and industry quality methodologies, including AHRQ, Elixhauser, HCCs, and CMS Star.
- Lead product lifecycle management from ideation through implementation and optimization.
- Ensure product roadmaps support evolving business requirements for the quality portfolio.
- Serve as the primary liaison between leadership, business stakeholders, technology teams, and executive sponsors.
- Facilitate alignment and decision-making across cross-functional teams.
- Communicate product vision, priorities, progress, and outcomes to senior leadership.
- Gather and incorporate stakeholder feedback into product planning and execution.
- Define and manage product epics, features, and user stories.
- Ensure Agile teams maintain a clear understanding of business priorities and expected outcomes.
- Define quality outcome metrics, key performance indicators, and performance dashboards.
- Use data analytics to identify return-on-investment outcome trends, risks, and improvement opportunities.
- Monitor product performance and value realization.
- Use customer and operational insights to inform product decisions.
- Comply with corporate policies, procedures, and security standards while performing assigned duties.
- A master's degree in business or a healthcare-related field.
- Ability to facilitate growth by sponsoring and championing new products, programs, and ideas through encouraging innovation.
- Ability to assess, design, and execute complex solutions in a sophisticated organization and translate them into client success.
- Industry and market knowledge related to clinical documentation integrity, quality methodologies, and coding solutions.
- Experience presenting successfully at industry trade shows and internal client events.
- Examples of successfully driving new product services.
- Experience with product development.
- Familiarity with Agile Scrum methodologies.
About the company
Solventum provides a wide range of healthcare products across four main areas: wound care and surgical supplies, dental and orthodontic tools, health information software, and purification filters for biopharmaceuticals. These products work by combining material science and data science to help hospitals manage patient records, prevent infections during surgery, and filter fluids for medical treatments like dialysis. Unlike many competitors, the company holds a massive portfolio of over 7,300 patents inherited from its history as a 3M division, allowing it to serve over 75% of U.S. hospitals. Its goal is to use this intellectual property and a disciplined business model to find new solutions for healthcare providers and grow within the global medical technology market.
Company Size
10,001+
Company Stage
IPO
Headquarters
Eagan, Minnesota
Founded
2023
Get referred to Solventum
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 organic sales rose 9.5%, and management raised EPS guidance to $7.10-$7.20.
- Solventum announced HIS separation on August 5, 2026, sharpening its MedTech focus.
- The $200 million Eagan Innovation Hub supports roughly 20 launches over two years.
What critics are saying
- Management expects HIS separation to cut margins about 400 basis points after offsets.
- ERP cutover orders distorted Q2 2026; Q3 growth resets when demand normalizes.
- Legal costs, restructuring, and separation complexity keep Solventum exposed until 2027-2028 transactions close.
What makes Solventum unique
- Solventum combines MedSurg, Dental, and clinical workflow assets from 3M’s healthcare spinout.
- Its 2026 Eagan Innovation Hub concentrates wound care, sterilization, and digital health R&D.
- The company still sells into over 75% of U.S. hospitals through entrenched workflows.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Relocation Assistance
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 5%2 year growth
↑ 9%BrightSpring Health Services stands out as a strong long-term healthcare investment, whilst Solventum and Inspire Medical Systems face headwinds, according to recent analysis. Healthcare stocks have surged 27.5% over the past six months, outperforming the S&P 500 by 16.2 percentage points. However, increased venture capital has intensified competition across the sector. BrightSpring, which provides home health care, hospice, and pharmacy services, has achieved 23.9% annual revenue growth over the past two years. Analysts forecast 14.1% revenue growth for the next 12 months. Conversely, Solventum faces weak demand with flat revenue expected, whilst its free cash flow margin has declined 18.2 percentage points over five years. Inspire Medical Systems confronts a forecasted revenue decline of 3.5% for the upcoming year.
Healthcare solutions provider Solventum reported second quarter revenue of $2.21 billion, up 2.2% year on year and ahead of analyst estimates of $2.15 billion. Non-GAAP profit of $2.55 per share beat consensus estimates by 33.8%. The company announced plans to separate its Health Information Systems business to focus on its MedSurg and Dental segments. Management said the move would allow the HIS unit to pursue AI-driven innovation whilst sharpening Solventum's focus as a pure-play MedTech company. Second quarter results were temporarily boosted by approximately $125 million in advanced orders placed ahead of a major ERP system transition, which management expects to reverse next quarter. The company raised its full-year adjusted EPS guidance to $7.15 at the midpoint, a 10% increase. Solventum is nearing completion of its separation from 3M.
Solventum exceeded expectations in Q2, posting $2.2 billion in sales with 9.5% organic growth. However, this included roughly $125 million in advanced ERP-related orders and a $100 million tariff refund. Excluding these benefits, organic growth was approximately 4% and adjusted EPS was estimated at $1.73. The company raised its 2026 outlook, now expecting 2.5%–3% organic sales growth, a 22.2%–22.7% operating margin, adjusted EPS of $7.10–$7.20, and free cash flow of $200 million–$300 million. Third-quarter growth is expected to decline temporarily as the advanced orders reverse. Solventum also announced plans to separate its Health Information Systems business through a potential spin-off or sale, aiming to focus on its MedSurg and Dental segments.
Solventum reported second quarter 2026 sales of $2.2 billion, up 2.2% on a reported basis and 9.5% organically. The MedTech company posted GAAP diluted earnings per share of $0.53 and adjusted diluted EPS of $2.55, marking a 50.9% increase. Operating cash flow reached $227 million, whilst free cash flow totalled $144 million. The strong performance was driven by volume and product mix across all segments, including advance orders ahead of ERP cutovers. Solventum announced plans to separate its Health Information Systems business segment as part of its transformation strategy. The company raised its full-year 2026 guidance, increasing organic sales growth to 2.5% to 3.0%, adjusted EPS to $7.10 to $7.20, and free cash flow to $200 million to $300 million.
Solventum has appointed Neil Zieselman as Senior Vice President, Controller, and Chief Accounting Officer. He will succeed Mary Wilcox, who is retiring. Zieselman brings experience from Surgery Partners, Stryker Corporation, Covanta Holding Corporation, Cendant Corporation, and Avaya. He is a licensed CPA. The company's stock trades at $85.44. It has delivered a 9.5% return over the past week and 19.1% over the past year. For investors, Zieselman's background in healthcare and corporate finance may influence Solventum's financial controls, reporting quality, and regulatory engagement. His approach could shape disclosure practices and capital allocation commentary in future earnings calls. Interest payments are not well covered by earnings, making any changes under the new Chief Accounting Officer particularly important for risk assessment.